LPA and coronary artery disorder: In addition, Lp(a) levels share interactions with systemic inflammatory biomarkers such as IL (interleukin) 6 and hsCRP (high-sensitivity C-reactive protein); IL6 inhibition reduces Lp(a) levels by ≈40%, while background hsCRP interacts with Lp(a)-driven cardiovascular risk.9,19–22 This suggests that high Lp(a) levels may increase as a result of systemic inflammation that characterizes patients with CAD and may be a rational therapeutic target in cardiovascular prevention.